"It appears that investors are more enthusiastic with Inovio's electroporation platform given the difference in market capitalization"
Some of the differentiation might not be about the platform optimism but rather the breadth of INO's platform such as the universal flu vaccine, which was not mentioned.
[Also, there is the difference of management (which Malc had strong feelings about) so that coudl very well be a factor beyond the science itself.]
I still own both but just wanted to point that out...